指南与共识神经核医学核素与放射性配体治疗

EANM/EANO/RANO/SNMMI联合实践指南/操作规范:使用放射性标记生长抑素受体配体对脑膜瘤进行诊断和治疗(诊疗一体化)第1.0版

Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0.
指南 / 共识 · Eur J Nucl Med Mol Imaging · 2024-06-20

该联合实践指南由EANM、SNMMI、EANO和PET/RANO工作组共同制定,旨在为脑膜瘤的SSTR配体PET诊断和PRRT治疗提供操作规范。指南指出SSTR PET可高灵敏度和高特异度检测脑膜瘤,并可能提供优于单独MRI或CT的临床相关信息;SSTR-PRRT是脑膜瘤的新兴研究性治疗手段。

要点

  • SSTR配体PET可高灵敏度和高特异度检测脑膜瘤组织,可能提供超越单独结构MRI或CT的临床信息。
  • SSTR导向PET尤其可用于鉴别诊断、勾画脑膜瘤范围、检测骨受累及区分治疗后瘢痕与肿瘤复发。
  • SSTR肽受体放射性核素治疗(PRRT)是脑膜瘤的新兴研究性治疗手段。

核心结论

  • 该实践指南定义了脑膜瘤患者PET成像及SSTR靶向PRRT在常规实践和临床试验中的操作标准,有助于统一各中心的数据采集与解读、促进研究可比性并收集更大数据库。

研究设计与样本

  • 本实践指南/操作规范由欧洲核医学协会(EANM)、核医学与分子影像学会(SNMMI)、欧洲神经肿瘤协会(EANO)及神经肿瘤反应评估工作组PET特别工作组(PET/RANO)合作制定。

主要发现

  • 使用生长抑素受体(SSTR)配体的正电子发射断层扫描(PET)能以高灵敏度和高特异度检测脑膜瘤组织,并可能提供超越单独结构磁共振成像(MRI)或计算机断层扫描(CT)成像所获信息的临床相关信息。
  • SSTR导向PET成像可能尤其有助于鉴别诊断、勾画脑膜瘤范围、检测骨受累以及区分治疗后瘢痕组织与肿瘤复发。
  • SSTR肽受体放射性核素治疗(PRRT)是脑膜瘤的一种新兴研究性治疗手段。

关键数值与推荐

  • 本文件为PET/RANO工作组关于脑膜瘤PET成像应用的循证推荐(Galldiks等,Neuro Oncol. 2017;19(12):1576-87)提供了补充信息。
  • 所提供信息应考虑当地条件和法规。

临床怎么用

  • 该指南旨在为脑膜瘤患者PET成像及SSTR靶向PRRT在常规实践和临床试验中定义操作标准,帮助各中心统一数据采集与解读、促进研究可比性并收集更大数据库。
  • 所提供信息应在当地条件和法规背景下考虑。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To provide practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor (SSTR) ligands. METHODS: This joint practice guideline/procedure standard was collaboratively developed by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neurooncology (EANO), and the PET task force of the Response Assessment in Neurooncology Working Group (PET/RANO). RESULTS: Positron emission tomography (PET) using somatostatin receptor (SSTR) ligands can detect meningioma tissue with high sensitivity and specificity and may provide clinically relevant information beyond that obtained from structural magnetic resonance imaging (MRI) or computed tomography (CT) imaging alone. SSTR-directed PET imaging can be particularly useful for differential diagnosis, delineation of meningioma extent, detection of osseous involvement, and the differentiation between posttherapeutic scar tissue and tumour recurrence. Moreover, SSTR-peptide receptor radionuclide therapy (PRRT) is an emerging investigational treatment approach for meningioma. CONCLUSION: These practice guidelines will define procedure standards for the application of PET imaging in patients with meningiomas and related SSTR-targeted PRRTs in routine practice and clinical trials and will help to harmonize data acquisition and interpretation across centers, facilitate comparability of studies, and to collect larger databases. The current document provides additional information to the evidence-based recommendations from the PET/RANO Working Group regarding the utilization of PET imaging in meningiomas Galldiks (Neuro Oncol. 2017;19(12):1576-87). The information provided should be considered in the context of local conditions and regulations.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Albert NL, Preusser M, Traub-Weidinger T, et al. Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0. Eur J Nucl Med Mol Imaging. 2024. PMID: 38898354. doi:10.1007/s00259-024-06783-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。